Drug intelligence / Profile preview

NS-031

Development stage: Preclinical
Lead developer: NeuShen Therapeutics
Modality: Small Molecules
Administration: Unspecified

Overview

NS-031 is a novel drug candidate being developed by NeuShen Therapeutics for the treatment of treatment-resistant depressive disorders. It is classified as an antidepressant, but its precise mechanism of action has not been defined or disclosed publicly. As of January 2025, it remains a new molecular entity in preclinical development, with no clinical trials or regulatory approvals reported. The compound is part of NeuShen's pipeline focused on central nervous system (CNS) disorders and aims to address unmet needs in depression that does not respond to standard therapies[1][4][9].

Other names: NS 031NS031NS-031

Beyond the preview

Go deeper on NS-031.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NS-031.

Explore the full profile